<DOC>
	<DOC>NCT00093145</DOC>
	<brief_summary>This trial will treat patients with advanced breast cancer with a new anti-cancer medicine used in combination with two existing anti-cancer medications: Albumin-bound paclitaxel (ABI-007), Carboplatin and Herceptin. Participants will be given the combination therapy on a weekly basis and may continue on therapy as long as their condition improves and drug toxicity is tolerated.</brief_summary>
	<brief_title>Study of Albumin-bound Paclitaxel (Abraxane) in Combination With Carboplatin and Herceptin in Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Confirmed adenocarcinoma of the breast Tumor shows 3+ overexpression of the human epidermal growth factor receptor 2 (HER2)/protooncogene by immunohistochemistry assay, or is fluorescence in situ hybridization (FISH)+ Stage IV disease Measurable disease At least 3 weeks since prior cytotoxic chemotherapy At least 4 weeks since radiotherapy with full recovery At least 4 weeks since major surgery with full recovery Eastern Cooperative Oncology Group (ECOG) performance status 02 At least 18 years old Absolute neutrophil count (ANC) at least 1.5 x 10^9 cells/L Platelets at least 100 x 10^9 cells/L Hemoglobin at least 9 g/dL Aspartame aminotransferase (AST), alanine aminotransferase (ALT) less than 2.5X upper limit normal Alkaline Phosphatase less than 1.5X upper limit normal Creatinine less than 1.5 gm/dL Normal left ventricular ejection fraction Negative pregnancy test Agree to use method to avoid pregnancy Informed Consent is obtained Up to one regimen of prior neoadjuvant or adjuvant chemotherapy is allowed. One year since Taxane and Herceptin treatment. Cumulative lifetime dose of doxorubicin is greater than 360 mg/m^2 Concurrent immunotherapy or hormonal therapy Parenchymal brain metastases, if present, must be documented to be clinically and radiographically stable for at least 6 months after treatment Serious intercurrent medical or psychiatric illness, including serious active infection History of congestive heart failure History of other malignancy within the last 5 years which could affect the diagnosis or assessment of breast cancer Patients who have received an investigational drug within the previous 3 weeks Patient is currently enrolled in another clinical study receiving investigational therapies Pregnant or nursing women</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Advanced Breast Cancer</keyword>
</DOC>